Allan Spiegel, MD
Neurology · Palm Harbor, FLNPI 1235148743
Payments from drug & device makers
Across 1,075 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$842
- Eisai Inc.$819
- Lundbeck LLC$790
- Lilly USA, LLC$786
- plus $12K from 49 others
What the payments were for
- Speaking & faculty fees$1201%
- Food & beverage$19,84099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART HYTRULO$235
- NURTEC ODT$125
- Duopa$124
- NUEDEXTA$124
- REXULTI$122
- AIMOVIG$119
How this compares
$19,959 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 26 | $306,642 |
| IngrezzaValbenazine Tosylate | 32 | $276,451 |
| QuliptaAtogepant | 150 | $231,235 |
| Kesimpta PenOfatumumab | 13 | $113,563 |
| RexultiBrexpiprazole | 25 | $63,181 |
| AptiomEslicarbazepine Acetate | 17 | $52,643 |
| UbrelvyUbrogepant | 30 | $41,298 |
| Aimovig AutoinjectorErenumab-Aooe | 45 | $41,133 |
| FycompaPerampanel | 19 | $39,078 |
| Nurtec OdtRimegepant Sulfate | 19 | $37,380 |
| BriviactBrivaracetam | 18 | $36,616 |
| GocovriAmantadine Hcl | 15 | $28,873 |
| Oxtellar XrOxcarbazepine | 18 | $26,620 |
| Memantine Hcl | 781 | $25,853 |
| Emgality PenGalcanezumab-Gnlm | 26 | $23,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $738 | $306,64226 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $718 | $276,45132 claims |
| AbbVieQulipta, Ubrelvy | $2,011 | $272,534180 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $842 | $63,18125 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $165 | $52,64317 claims |
| Eisai Inc.Fycompa, Dayvigo | $819 | $46,17331 claims |
| PfizerNurtec Odt | $701 | $37,38019 claims |
| UCB, Inc.Briviact | $2,387 | $36,61618 claims |
| MDD US Operations, LLCGocovri | $386 | $28,87315 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $578 | $26,62018 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $225 | $22,24249 claims |
| SK Life Science, Inc.Xcopri | $654 | $19,06416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.
Other neurology in Palm Harbor
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.